STRESSGEN'S EUROPEAN PATENT UPHELD AGAINST ANTIGENICS' CHALLENGE
Stressgen Biotechnologies (TSX: SSB) today announced that it has received a favorable decision in its patent challenge by Antigenics from an Opposition Division of the European Patent Office that maintained the Company's European Patent EP-B1 1,002,110 in amended form. The Opposition by Antigenics was therefore dismissed, although they have the right to appeal this decision. Oppositions can be filed by third parties at the European Patent Office against European patents to challenge their validity.
Canada NewsWire (http://www.newswire.ca/en/releases/archive/October2005/19/c3386.html)